Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Survival Impact of Repeated Endobiliary Radiofrequency Ablation in Patients Undergoing Durvalumab Plus Gemcitabine and Cisplatin for Extrahepatic Cholangiocarcinoma: An International Multicenter Randomized Controlled Trial (BRAVE Trial)

NCT07235007 is registered in ClinicalTrials.gov with Aichi Medical University as lead sponsor.

NCT NCT07235007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07235007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Survival Impact of Repeated Endobiliary Radiofrequency Ablation in Patients Undergoing Durvalumab Plus Gemcitabine and Cisplatin for Extrahepatic Cholangiocarcinoma: An International Multicenter Randomized Controlled Trial (BRAVE Trial)
Lead sponsor
Aichi Medical University
Phase
Not applicable
Overall status
Recruiting
Start date
November 20, 2025
Completion date
December 31, 2030
Enrollment
120 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

extrahepatic cholangiocarcinoma